Search by Drug Name or NDC

    NDC 45737-0227-16 BioTPres 5; 75; 2.5 mg/5mL; mg/5mL; mg/5mL Details

    BioTPres 5; 75; 2.5 mg/5mL; mg/5mL; mg/5mL

    BioTPres is a ORAL LIQUID in the HUMAN OTC DRUG category. It is labeled and distributed by Advanced Generic Corporation. The primary component is DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE.

    Product Information

    NDC 45737-0227
    Product ID 45737-227_b5c27388-e0e3-4924-bb72-2386229f78b5
    Associated GPIs 43997303100907
    GCN Sequence Number 058870
    GCN Sequence Number Description guaifen/dextromethorphan/PE LIQUID 75-5-2.5/5 ORAL
    HIC3 B4R
    HIC3 Description NON-OPIOID ANTITUSSIVE-DECONGESTANT-EXPECTORANT
    GCN 24395
    HICL Sequence Number 000216
    HICL Sequence Number Description GUAIFENESIN/DEXTROMETHORPHAN HBR/PHENYLEPHRINE
    Brand/Generic Generic
    Proprietary Name BioTPres
    Proprietary Name Suffix Pediatric
    Non-Proprietary Name Dextromethorphan, Guaifenesin, Phenylephrine
    Product Type HUMAN OTC DRUG
    Dosage Form LIQUID
    Route ORAL
    Active Ingredient Strength 5; 75; 2.5
    Active Ingredient Units mg/5mL; mg/5mL; mg/5mL
    Substance Name DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
    Labeler Name Advanced Generic Corporation
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2022-12-31

    Package

    NDC 45737-0227-16 (45737022716)

    NDC Package Code 45737-227-16
    Billing NDC 45737022716
    Package 473 mL in 1 BOTTLE (45737-227-16)
    Marketing Start Date 2009-10-01
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL d6b2d191-e2fb-4da4-92e0-35b81e07e673 Details

    Revised: 12/2020